5-RCT meta-analysis confirms tesamorelin visceral fat effect
Five tesamorelin RCTs pooled in a 2026 meta-analysis: visceral fat down 27.71 cm², trunk fat down 1.18 kg in HIV lipodystrophy, with no glycemic worsening.
May 12, 2026 · 3 min read
A 2026 meta-analysis pooling five randomized controlled trials of tesamorelin in HIV-associated lipodystrophy quantifies the GHRH analog's central fat effect with precision: visceral adipose tissue fell by a mean 27.71 cm² (P < 0.001) and trunk fat by 1.18 kg, with no adverse glycemic or lipid signal across the included trials.
What happened
Hazem Ayesh, Ahmed Samy Badran, Abdulrhman Helal, and Karim Samir Shata searched five major databases through July 2025 and identified five RCTs of sufficient quality to pool. All trials compared tesamorelin against placebo in adults with HIV-associated lipodystrophy.
Pooled findings on the primary endpoints:
- Visceral adipose tissue: mean difference −27.71 cm² (95% CI −38.37 to −17.06; P < 0.001)
- Trunk fat: mean difference −1.18 kg (95% CI −1.40 to −0.95)
- Waist circumference: statistically significant reduction
- Hepatic fat: statistically significant reduction
- Lean body mass: modest but significant increase
Crucially, neither glycemic parameters nor lipid profiles showed significant worsening. Tesamorelin raises IGF-1 by stimulating endogenous growth hormone secretion, and elevated IGF-1 can in principle worsen insulin resistance — a safety question that has followed the compound since its Phase 3 trials. The meta-analysis data across five trials does not resolve that theoretical concern definitively, but the pooled signal does not support a clinical harm at the studied doses.
Tesamorelin (branded Egrifta, and in the once-weekly EGRIFTA WR formulation approved by the FDA in March 2025) is the only GHRH analog with an approved therapeutic indication. It holds a distinct position among the compounds discussed in GH secretagogue contexts: an approved drug with an established Phase 3 evidence base, a manufacturer, and a labeled dosing protocol — unlike the gray-market GHRH-pathway peptides CJC-1295 and Sermorelin, which share a mechanistic similarity but have not cleared a comparable evidence hurdle.
Why it matters
The meta-analysis consolidates the most complete picture yet of what GHRH-pathway stimulation can achieve in a human population. Its findings — specific quantification of fat reduction, safety across five trials — provide a benchmark that is directly relevant to evaluating the unapproved GHRH-pathway compounds.
As GH secretagogues attract growing interest for body composition and recovery outside their HIV-lipodystrophy origins, the tesamorelin evidence base is the best available approximation of what sustained GHRH stimulation produces in vivo. The meta-analysis's clean safety profile on glycemic parameters strengthens the pharmacological rationale for the class, even as it underscores how much remains uncharacterized for the off-label compounds.
Tesamorelin is also relevant to the July 2026 PCAC discussion. The advisory committee will review seven peptides for potential 503A compounding status, including GHRH-adjacent compounds. The meta-analysis may enter the background evidence review as context for how a well-studied GHRH analog performs — and how far the unapproved analogs fall from that evidentiary standard.
What to watch
- Whether the meta-analysis evidence prompts updated clinical guidelines for tesamorelin in HIV lipodystrophy, particularly in the context of integrase inhibitor–based regimens now standard in HIV care
- NCT06554717, a registered trial examining tesamorelin combined with exercise — if that trial reads out, it will be the first evidence for tesamorelin in a non-HIV metabolic population
- Whether PCAC committee materials for the July meeting cite the meta-analysis as reference for the GHRH-class evidence standard, effectively establishing a comparator for what approved clinical evidence looks like versus what the gray-market compounds can offer
Sources
Sources